The leading players such as IBA Group , Lantheus Medical
Imaging , NTP Radioisotopes , Siemens Healthcare (PETNET Solutions), & Triad Isotopes in global Nuclear Medicine
Therapeutics market have focused on expanding their presence globally through
expansions, acquisitions, and agreements. Thus, increasing investment by
leading players in the region coupled with investments from central & local
government agencies creates significant growth opportunities.
The global
nuclear medicine therapeutics market is expected to grow from an estimated USD
1.09billion in 2014 to USD 2.09 billion in 2019, at a CAGR of 13.91%.
Global Nuclear Medicine Therapeutics Market-Market Dynamics
The report details several driving and restraining factors for the market. Some of these are listed below.
Global Nuclear Medicine Therapeutics Market-Market Dynamics
The report details several driving and restraining factors for the market. Some of these are listed below.
Drivers
The major factors
contributing to the growth of the market are:
Increasing use of SPECT and PET analysis in radiopharmaceuticals
Increased awareness in people for radiopharmaceuticals
Ready availability of radiopharmaceuticals
Novel applications such as Alzheimer‰Ûªs
Continually expanding oncology application segment
Increasing use of SPECT and PET analysis in radiopharmaceuticals
Increased awareness in people for radiopharmaceuticals
Ready availability of radiopharmaceuticals
Novel applications such as Alzheimer‰Ûªs
Continually expanding oncology application segment
Restraints
Some of the factors
restraining market growth are:
Complex FDA toxicology and other regulatory requirements
Lack of specific guidelines from the FDA for good manufacturing practices of radiopharmaceuticals
Lack of consensus for standardized image acquisition in nuclear imaging procedures
Therapeutic nuclear medicine finds its application in the treatment of various types of cancer such as lymphoma, bone metastasis, thyroid, endocrine tumors etc. Radionuclide therapy has unique promise as a vehicle for personalized treatment of cancer. Alpha emitters that use bismuth-213 and astatine-211 labeled monoclonal antibodies in patients with leukemia and brain tumor and radium- 223 are being evaluated in breast and prostate cancer patients with bone metastases. Beta emitters are currently limited to yttrium-90 and iodine-131, which are used in the treatment of non-Hodgkins lymphoma, samarium-153-EDTMP, and strontium-89-chloride for palliation of bone metastases. The market scope of preclinical and clinical research in the therapy field is much broader.
Complex FDA toxicology and other regulatory requirements
Lack of specific guidelines from the FDA for good manufacturing practices of radiopharmaceuticals
Lack of consensus for standardized image acquisition in nuclear imaging procedures
Therapeutic nuclear medicine finds its application in the treatment of various types of cancer such as lymphoma, bone metastasis, thyroid, endocrine tumors etc. Radionuclide therapy has unique promise as a vehicle for personalized treatment of cancer. Alpha emitters that use bismuth-213 and astatine-211 labeled monoclonal antibodies in patients with leukemia and brain tumor and radium- 223 are being evaluated in breast and prostate cancer patients with bone metastases. Beta emitters are currently limited to yttrium-90 and iodine-131, which are used in the treatment of non-Hodgkins lymphoma, samarium-153-EDTMP, and strontium-89-chloride for palliation of bone metastases. The market scope of preclinical and clinical research in the therapy field is much broader.
Purchase a copy of Global Nuclear
Medicine Therapeutics Market visit @ http://www.orbisresearch.com/contact/purchase/219739 For more
information contact sales@orbisresearch.com .
The number
of therapeutic procedures in North America, Europe, and Asia-Pacific is 265,
22,195, and 271,248 for the year 2013 respectively. Talking about country-wise
therapeutic procedures, the US has 262 therapeutic procedures. Developing
countries like India hold strong market potential, accounting for 7475
therapeutic procedures.
The market
is segmented into Beta Emitters (Iodine-131 (I-131), Yttrium-90 (Y-90),
Samarium-153 (SM-153), Rhenium-186 (RE-186), Lutetium-177 (LU-177)and Others);
Alpha Emitters(Radium-223 (RA-223) & Alpharadin, Actinium-225 (AC-225),
Lead-212 (PB-212)/Bismuth-212 (BI-212)and Astatine-211 (AT-211)) and
Brachytherapy (Cesium-131, Iodine-125, Palladium-103 and Iridium-192), applications
and geography ( North America, Europe and Asia-Pacific).
Mergers and acquisitions of small and medium-sized manufacturers to enter the overseas market is a strategy adopted by multinational players.
Mergers and acquisitions of small and medium-sized manufacturers to enter the overseas market is a strategy adopted by multinational players.
Some of the key
players in the market are:
IBA Group
Lantheus Medical Imaging
NTP Radioisotopes
Siemens Healthcare (PETNET Solutions)
Triad Isotopes
IBA Group
Lantheus Medical Imaging
NTP Radioisotopes
Siemens Healthcare (PETNET Solutions)
Triad Isotopes
What the Report
Offers
Market definition for the global nuclear medicine therapeutic (Alpha Emitters, Beta Emitters, and Brachytherapy) market along with identification of key drivers and restraints for the market.
Market analysis for the nuclear medicine therapeutic (Alpha Emitters, Beta Emitters, and Brachytherapy) with region-specific assessments and competition analysis on a global and regional scale.
Market definition for the global nuclear medicine therapeutic (Alpha Emitters, Beta Emitters, and Brachytherapy) market along with identification of key drivers and restraints for the market.
Market analysis for the nuclear medicine therapeutic (Alpha Emitters, Beta Emitters, and Brachytherapy) with region-specific assessments and competition analysis on a global and regional scale.
Browse Complete Report @ http://www.orbisresearch.com/reports/index/global-nuclear-medicine-therapeutics-market-alpha-emitters-beta-emitters-and-brachytherapy-analysis-and-forecasts-2017-2022 .
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.
An ideal opportunity for industry consultants and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
Wide-ranging information provided about the leading market players and the major strategies adopted by them.
Some points from TOC:
1. INTRODUCTION
1.1 Market Definition
1.2 Market Size Estimation
1.1 Market Definition
1.2 Market Size Estimation
2. Key Findings
3. Executive Summary
4. Market Overview
4.1 Definition of radiopharmaceuticals
4.2 Market Share Analysis
4.3 Market dynamics
4.3.1 Market Drivers
4.3.1.1 Increasing incidents of Cancer and Cardiac ailments
4.3.1.2 Increasing awareness of radiopharmaceuticals
4.3.1.3 Public Awareness
4.3.1.4 Ready availability of radiopharmaceuticals
4.3.2 Market Restraints
4.3.2.1 Shorter half-life of radiopharmaceuticals
4.3.2.2 High capital investment
4.3.2.3 Regulatory Guidelines
4.3.2.4 Reimbursement issues
4.3.3 Market Opportunities
4.3.3.1 Potential radioisotopes in pipeline
4.3.3.2 Increasing neurological applications
4.3.3.3 Cyclotron based production
4.3.4 Threat
4.3.4.1 Shutdown of Nuclear reactors
4.1 Definition of radiopharmaceuticals
4.2 Market Share Analysis
4.3 Market dynamics
4.3.1 Market Drivers
4.3.1.1 Increasing incidents of Cancer and Cardiac ailments
4.3.1.2 Increasing awareness of radiopharmaceuticals
4.3.1.3 Public Awareness
4.3.1.4 Ready availability of radiopharmaceuticals
4.3.2 Market Restraints
4.3.2.1 Shorter half-life of radiopharmaceuticals
4.3.2.2 High capital investment
4.3.2.3 Regulatory Guidelines
4.3.2.4 Reimbursement issues
4.3.3 Market Opportunities
4.3.3.1 Potential radioisotopes in pipeline
4.3.3.2 Increasing neurological applications
4.3.3.3 Cyclotron based production
4.3.4 Threat
4.3.4.1 Shutdown of Nuclear reactors
For any enquires
before buying, connect with us @ enquiry@orbisresearch.com
About Us:
Orbis Research (orbisresearch.com) is a
single point aid for all your market research requirements. We have vast
database of reports from the leading publishers and authors across the globe.
We specialize in delivering customized reports as per the requirements of our
clients. We have complete information about our publishers and hence are sure
about the accuracy of the industries and verticals of their specialization.
This helps our clients to map their needs and we produce the perfect required
market research study for our clients.
Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research
Follow us on Twitter:
https://twitter.com/orbisresearch
Like
us on Facebook: https://www.facebook.com/OrbisResearch
No comments:
Post a Comment